Figure 1.

Clinical features of our patients and a literature review of previously reported STAT3-GOF patients treated with JAK inhibitors. Patients No. 1–4 are in the patient 1–4 of this study, Patients No. 5–10 are in the patient 12–17 of the study by Forbes et al. [11], No. 11 is in the report of Parlato et al. [10], Patient No. 12–14 are in the patient 1, 2, and 4 in the study by Silva-Carmona et al. [14], Patient No. 15 is in the report by Wegehaupt et al. [15], Patient No. 16 is the report by Sarfati et al. [16], and Patient No. 17 is in the report by Mulvihill et al. [13]. Symptoms highlighted in green cells are complete or partially responded symptoms. Symptoms highlighted in gray cells are not responded symptoms or not described for the responses in the reports. CNS, central nervous system; JAK, Janus kinase; JAKi, JAK inhibitors; N.D., No data.